Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses

Diana F. Florescu, Megan A. Keck

Research output: Contribution to journalReview articlepeer-review

63 Scopus citations

Abstract

CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.

Original languageEnglish (US)
Pages (from-to)1171-1178
Number of pages8
JournalExpert Review of Anti-Infective Therapy
Volume12
Issue number10
DOIs
StatePublished - Oct 1 2014

Keywords

  • BK virus
  • Brincidofovir
  • CMX001
  • JC virus
  • adenovirus
  • cytomegalovirus
  • dsDNA virus
  • molluscum
  • orthopoxvirus
  • vaccinia virus

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses'. Together they form a unique fingerprint.

Cite this